Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Recurrent or Metastatic Head and Neck cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Recurrent or Metastatic Head and Neck cancer Pipeline Report

* DelveInsight's Recurrent or Metastatic Head and Neck cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck cancer treatment.
* The leading Recurrent or Metastatic Head and Neck cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
* Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
* June 2024:- AVEO Pharmaceuticals Inc.- The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.
* May 2024:- Alentis Therapeutics Inc- A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.

Explore our comprehensive Recurrent or Metastatic Head and Neck Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Recurrent or Metastatic Head and Neck Cancer Overview

Traditionally patients with recurrence of head and neck cancer (HNC) are considered to have poor prognosis. As a result the majority of these patients are usually treated with palliative intent or receive best supportive care. Head and neck cancers are the sixth most common cancer worldwide, and arise from the upper aerodigestive mucosa, salivary glands, and skin. Despite differences in histology and biology across cancer types, most treatment protocols are extrapolated from head and neck squamous cell carcinoma (HNSCC the most common histology. Recurrent and metastatic disease is usually incurable. There are significant gaps in knowledge. Unlike other cancer types, there are no predictive biomarkers, and no new targeted therapies have been approved for HNSCC other than cetuximab in 2006.

Recurrent or Metastatic Head and Neck cancer Emerging Drugs

* Xevinapant: Merck

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive 188 million upfront and up to 710 million in regulatory and commercial milestones, as well as royalty payments

* SI B001: Sichuan Baili Pharmaceutical

SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR times EGFR homodimers, the formation of EGFR times HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.

Dive into our Recurrent or Metastatic Head and Neck Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Recurrent or Metastatic Head and Neck Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Recurrent or Metastatic Head and Neck Cancer Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies Recurrent or Metastatic Head and Neck cancer. The companies which have their Recurrent or Metastatic Head and Neck cancer drug candidates in the most advanced stage, i.e phase III include Eisai Co

DelveInsight's Recurrent or Metastatic Head and Neck Cancer pipeline report covers around 40+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Download the Recurrent or Metastatic Head and Neck Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Recurrent or Metastatic Head and Neck Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous

Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Dive into our detailed Recurrent or Metastatic Head and Neck Cancer Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ Recurrent or Metastatic Head and Neck Cancer Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

* Coverage- Global
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
* Recurrent or Metastatic Head and Neck Cancer Therapies- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.

Gain valuable insights into emerging therapies and innovations with our Recurrent or Metastatic Head and Neck Cancer Pipeline Report @ Recurrent or Metastatic Head and Neck Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Recurrent or Metastatic Head and Neck cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Recurrent or Metastatic Head and Neck cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lenvatinib: Eisai Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SI B001: Sichuan Baili Pharmaceutical
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Revdofilimab: AbbVie
* Drug profiles in the detailed report.....
* Early Stage Products (Preclinical)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Recurrent or Metastatic Head and Neck cancer Key Products
* Recurrent or Metastatic Head and Neck cancer- Unmet Needs
* Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
* Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
* Recurrent or Metastatic Head and Neck cancer Analyst Views
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=recurrent-or-metastatic-head-and-neck-cancer-pipeline-outlook-report-2024-updated]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.